Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial

Govaert, Th. M. E.; Sprenger, M. J. W.; Dinant, Geert Jan; Aretz, Karin; Masurel, N.; Knottnerus, J.A.

doi:10.1016/0264-410x(94)90241-0

Cited by 125 publications

(53 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the elderly, the response is not as good. Between 30-70% reach an HI titre of .1:40 [260][261][262][263]. In these age groups, a double dose, or a booster dose, has been shown to increase the geometric mean IgG antibody concentration by ,15% [264].…”

Section: Prevention By Vaccinationmentioning

confidence: 96%

Guidelines for the management of adult lower respiratory tract infections

Woodhead¹

2005

Eur Respir J

685

555

View full text Add to dashboard Cite

Section: Prevention By Vaccinationmentioning

confidence: 96%

Guidelines for the management of adult lower respiratory tract infections

Woodhead¹

2005

Eur Respir J

685

555

View full text Add to dashboard Cite

“…Influenza vaccination in the previous year was associated with a lower seroconversion rate to A/H1N1; both vaccines contained the same A/H1N1 strain. The effects of previous influenza vaccination on antibody responses remain subject to discussion, because some studies demonstrated decreased antibody responses (34)(35)(36), whereas others showed similar (37)(38)(39) or improved responses (40).…”

Section: Discussionmentioning

confidence: 99%

Studies of cell‐mediated immune responses to influenza vaccination in systemic lupus erythematosus

Holvast¹,

Assen²,

Haan³

et al. 2009

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. Both antibody and cell-mediated responses are involved in the defense against influenza. In patients with systemic lupus erythematosus (SLE), a decreased antibody response to subunit influenza vaccine has been demonstrated, but cell-mediated responses have not yet been assessed. This study was therefore undertaken to assess cell-mediated responses to influenza vaccination in patients with SLE.Methods. Fifty-four patients with SLE and 54 healthy control subjects received subunit influenza vaccine. Peripheral blood mononuclear cells and sera were obtained before and 1 month after vaccination. Cellmediated responses to A/H1N1 and A/H3N2 vaccines were evaluated using an interferon-␥ (IFN␥) enzymelinked immunospot assay and flow cytometry. Antibody responses were measured using a hemagglutination inhibition test.Results. Prior to vaccination, patients with SLE had fewer IFN␥ spot-forming cells against A/H1N1 compared with control subjects and a lower frequency of IFN␥-positive CD8؉ T cells. After vaccination, the number of IFN␥ spot-forming cells increased in both patients and control subjects, although the number remained lower in patients. In addition, the frequencies of CD4؉ T cells producing tumor necrosis factor and interleukin-2 were lower in patients after vaccination compared with healthy control subjects. As expected for a subunit vaccine, vaccination did not induce a CD8؉ T cell response. For A/H3N2-specific responses, results were comparable. Diminished cell-mediated responses to influenza vaccination were associated with the use of prednisone and/or azathioprine. The increase in A/H1N1-specific and A/H3N2-specific antibody titers after vaccination was lower in patients compared with control subjects.Conclusion. In addition to a decreased antibody response, cell-mediated responses to influenza vaccination are diminished in patients with SLE, which may reflect the effects of the concomitant use of immunosuppressive drugs. This may render these patients more susceptible to (complicated) influenza infections.

show abstract

“…Unfortunately, antibody responses to influenza virus in elderly persons show reduced levels of both IgG and IgA antibodies, delayed peak antibody titers, and shorter maintenance of antibody titers (8,13,23). Studies with rodents indicate that during aging a progressively increasing proportion of nonfunctional cells results in decreased T-cell proliferation, IL-2 production, and cytotoxicity (33).…”

Section: Vol 78 2004 Lt-is Patch Enhances Influenza Virus Vaccinatimentioning

confidence: 99%

Immunostimulant Patch Enhances Immune Responses to Influenza Virus Vaccine in Aged Mice

Guebre‐Xabier

Hammond

Ellingsworth

et al. 2004

J Virol

View full text Add to dashboard Cite

Improvement in the immune response to influenza virus vaccination in the elderly represents the primary unmet need in influenza virus vaccination. We have shown that topical application of immunostimulating (IS) patches containing heat-labile enterotoxin of Escherichia coli (LT) enhances immune responses to injected vaccines. We extend these findings and show that LT-IS patch application enhances the antibody responses to influenza virus vaccination in both young and aged mice. LT-IS patches markedly increased influenza virusspecific immunoglobulin G (IgG), hemagglutination inhibition antibody, mucosal antibody, and T-cell responses. The magnitude of the immune responses in aged mice receiving an LT-IS patch was equivalent to or greater than that of the immune responses in young mice given vaccine alone. These results suggest that addition of an LT-IS patch may compensate for the deficient immune function seen in the aged in response to influenza virus vaccination. Therefore, use of an LT-IS patch could be a new, safe, and simple immunization strategy that may significantly improve the outcome of influenza virus vaccination in the elderly.

show abstract

Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial

Cited by 125 publications

References 19 publications

Guidelines for the management of adult lower respiratory tract infections

Guidelines for the management of adult lower respiratory tract infections

Studies of cell‐mediated immune responses to influenza vaccination in systemic lupus erythematosus

Immunostimulant Patch Enhances Immune Responses to Influenza Virus Vaccine in Aged Mice

Contact Info

Product

Resources

About